(Q36624086)

15 August 2017

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin (English)

1 reference

15 August 2017

1 reference

12

J H Beijnen

1 reference

15 August 2017

W W ten Bokkel Huinink

14

object named as

W W ten Bokkel Huinink

1 reference

15 August 2017

N E Schoemaker

1

1 reference

15 August 2017

C van Kesteren

2

1 reference

15 August 2017

H Rosing

3

1 reference

15 August 2017

S Jansen

4

1 reference

15 August 2017

M Swart

5

1 reference

15 August 2017

J Lieverst

6

1 reference

15 August 2017

D Fraier

7

1 reference

15 August 2017

M Breda

8

1 reference

15 August 2017

C Pellizzoni

9

1 reference

15 August 2017

R Spinelli

10

1 reference

15 August 2017

M Grazia Porro

11

1 reference

15 August 2017

J H M Schellens

13

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

87

1 reference

15 August 2017

608-614

1 reference

15 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600516

15 August 2017

0 references

cites work

Modulation of camptothecin analogs in the treatment of cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Clinical pharmacokinetics of irinotecan

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

The current status of camptothecin analogues as antitumor agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Passive tumor targeting of soluble macromolecules and drug conjugates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Camptothecin. Discovery to clinic

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Comparison of methods of estimating creatinine clearance in children.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364251

Polymer-bound camptothecin: initial biodistribution and antitumour activity studies

20 September 2018

1 reference

12 December 2020

Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600516

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference